The Use of Probiotic Therapy in Metabolic and Neurological Diseases

• Published in: Frontiers in nutrition (Lausanne) Vol. 9; p. 887019
• Main Authors: Lee, Shirley H F, Ahmad, Siti R, Lim, Ya C, Zulkipli, Ihsan N
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 03.05.2022
• Subjects: diabetes; microbes; neurodegenerative diseases; Nutrition; obesity; probiotics; therapy; neurodegenerative diseases; microbes; diabetes; therapy; obesity; probiotics
• ISSN: 2296-861X; 2296-861X
• DOI: 10.3389/fnut.2022.887019

The human gut is home to trillions of microbes that interact with host cells to influence and contribute to body functions. The number of scientific studies focusing on the gut microbiome has exponentially increased in recent years. Studies investigating factors that may potentially affect the gut microbiome and may be used for therapeutic purposes in diseases where dysbioses in the gut microbiome have been shown are of particular interest. This review compiles current evidence available in the scientific literature on the use of probiotics to treat metabolic diseases and autism spectrum disorders (ASDs) to analyze the efficacy of probiotics in these diseases. To do this, we must first define the healthy gut microbiome before looking at the interplay between the gut microbiome and diseases, and how probiotics affect this interaction. In metabolic diseases, such as obesity and diabetes, probiotic supplementation positively impacts pathological parameters. Conversely, the gut-brain axis significantly impacts neurodevelopmental disorders such as ASDs. However, manipulating the gut microbiome and disease symptoms using probiotics has less pronounced effects on neurodevelopmental diseases. This may be due to a more complex interplay between genetics and the environment in these diseases. In conclusion, the use of microbe-based probiotic therapy may potentially have beneficial effects in ameliorating the pathology of various diseases. Validation of available data for the development of personalized treatment regimens for affected patients is still required.